← back to search

Sven Francque

Inova Health System · BE
Area of research
Epidemiology · Hepatology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Diet, Metabolism, and Disease, and Hepatitis C virus research.
h-index
80
citations
35,162
works
447
NIH funding
primary concept
Medicine
email

Recent publications

Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of <scp>MASLD</scp>
Liver International 2025cited by 12position: middledoi
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Hepatology 2025cited by 6position: middledoi
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
New England Journal of Medicine 2024cited by 1,611position: middledoi
Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease
Journal of Hepatology 2024cited by 124position: middledoi
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
Nature Medicine 2024cited by 118position: middledoi
Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
Journal of Hepatology 2024cited by 59position: middledoi
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease
JHEP Reports 2024cited by 29position: middledoi
Spleen Stiffness–Based Algorithms Are Superior to Baveno VI Criteria to Rule Out Varices Needing Treatment in Patients With Advanced Chronic Liver Disease
The American Journal of Gastroenterology 2024cited by 17position: middledoi
A turning point in hepatology? EASL reflects on the first approved drug for MASH
Journal of Hepatology 2024cited by 13position: firstdoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Hepatology 2023cited by 2,786position: middledoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Journal of Hepatology 2023cited by 2,592position: middledoi
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Annals of Hepatology 2023cited by 781position: middledoi
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Hepatology 2023cited by 392position: middledoi
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
New England Journal of Medicine 2023cited by 245position: middledoi
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
˜The œLancet. Gastroenterology & hepatology 2023cited by 186position: middledoi
A global research priority agenda to advance public health responses to fatty liver disease
Journal of Hepatology 2023cited by 128position: middledoi
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Journal of Hepatology 2023cited by 94position: middledoi
A global action agenda for turning the tide on fatty liver disease
Hepatology 2023cited by 83position: middledoi
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Hepatology 2023cited by 63position: middledoi
Implementation of a liver health check in people with type 2 diabetes
˜The œLancet. Gastroenterology & hepatology 2023cited by 59position: middledoi
Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH
Journal of Hepatology 2023cited by 38position: middledoi
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives
Journal of Hepatology 2023cited by 34position: lastdoi
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study
Hepatology 2023cited by 33position: middledoi
A multistakeholder approach to innovations in NAFLD care
Communications Medicine 2023cited by 32position: middledoi
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials
Journal of Hepatology 2023cited by 14position: middledoi
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
Nature Reviews Gastroenterology & Hepatology 2022cited by 230position: middledoi
Non-invasive tests for clinically significant portal hypertension after HCV cure
Journal of Hepatology 2022cited by 83position: middledoi
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice
JHEP Reports 2022cited by 46position: middledoi
Baveno VII – Renewing consensus in portal hypertension
Journal of Hepatology 2021cited by 2,566position: middledoi
Advancing the global public health agenda for NAFLD: a consensus statement
Nature Reviews Gastroenterology & Hepatology 2021cited by 722position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jörn M. Schattenberg · Universitätsklinikum des Saarlandes6 papers (2016–2024)Vlad Ratziu · Inserm5 papers (2014–2020)Jeffrey V. Lazarus · The Graduate Center, CUNY5 papers (2021–2023)Luc Van Gaal · Antwerp University Hospital5 papers (2015–2021)Manal F. Abdelmalek · Mayo Clinic5 papers (2017–2023)Rohit Loomba · Indiana University – Purdue University Indianapolis5 papers (2017–2022)Arun J. Sanyal · Center for Systems Biology5 papers (2017–2023)Zobair M. Younossi · NIHR Birmingham Biomedical Research Centre4 papers (2020–2023)Mary E. Rinella · Sungkyunkwan University4 papers (2019–2023)Quentin M. Anstee · Newcastle upon Tyne Hospital4 papers (2016–2022)Frederik Nevens · European Union3 papers (2014–2016)Frank Tacke · Charité University Medicine Berlin3 papers (2017–2020)Guruprasad P. Aithal · NIHR Nottingham Hearing Biomedical Research Unit3 papers (2014–2020)Stephen A. Harrison · Oxford Centre for Diabetes, Endocrinology and Metabolism3 papers (2017–2020)Vincent Wai‐Sun Wong · Second Affiliated Hospital of Xi'an Jiaotong University3 papers (2017–2022)Laurent Fischer · Allergan (Ireland)3 papers (2017–2020)Alina M. Allen · Mayo Clinic3 papers (2022–2023)David Cassiman · KU Leuven3 papers (2015–2024)Shira Zelber‐Sagi · Tel Aviv University3 papers (2021–2024)Elisabetta Bugianesi · Indiana University – Purdue University Indianapolis3 papers (2016–2022)